Inhibition of posterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results

Clark, Donald S.; Emery, Jared M.; Munsell, Mark E.

doi:10.1016/s0886-3350(98)80352-0

Cited by 49 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corneal opacification [184] Strabismus [185] Pain killing (destruction of sensitive nerves) [186] 1858 F. Stirpe and M. G. Battelli Ribosome-inactivating Proteins: Progresses and Problems far, the use of immunotoxins in cancer therapy has not fulfilled the hopes, undoubtedly excessive, which were raised when they came out. The main difficulties are summarized in Table 4.…”

Section: Removal Of Cells From Cultures [175]mentioning

confidence: 99%

“…Other possible uses of immunotoxins in ophthalmology have been explored, for the treatment of posterior capsule opacification, for which some clinical trials have been performed [184,196], and to prevent corneal cell proliferation [197]. A number of interesting results were obtained with the use of saporin-containing immunotoxins and other conjugates directed against a variety of nervous cells.…”

Section: Removal Of Cells From Cultures [175]mentioning

confidence: 99%

See 1 more Smart Citation

Ribosome-inactivating proteins: progress and problems

Stirpe

Battelli

2006

Cell. Mol. Life Sci.

321

225

View full text Add to dashboard Cite

Ribosome-inactivating proteins (RIPs), mostly from plants, are enzymes which depurinate rRNA, thus inhibiting protein synthesis. They also depurinate other polynucleotide substrates. The biological activity of RIPs is not completely clarified, and sometimes independent of the inhibition of protein synthesis. There are differences in the cytotoxicity of RIPs and, consequently, in their toxicity to animals. Some RIPs are potent toxins, the best known being ricin, a potential biological weapon. New toxins have recently been identified. RIPs cause apoptotic and necrotic lesions, and induce production of cytokines causing inflammation. RIPs are potentially useful in agriculture and medicine because (i) they have antiviral activity and (ii) they are used for the preparation of conjugates with antibodies ('immunotoxins') or other carriers, rendering them specifically toxic to the cell target of the carrier, which may be helpful in therapy. The distribution, mechanism of action and role in nature of RIPs are not completely understood, and we can expect several future developments in their practical application.

show abstract

Section: Removal Of Cells From Cultures [175]mentioning

confidence: 99%

Section: Removal Of Cells From Cultures [175]mentioning

confidence: 99%

Ribosome-inactivating proteins: progress and problems

Stirpe

Battelli

2006

Cell. Mol. Life Sci.

321

225

View full text Add to dashboard Cite

show abstract

“…One of the most effective methods to diminish PCO has been intraoperative treatment with an immunotoxin against LECs (MDX-A), 11 reported to significantly lower the PCO rate but not prevent it completely. Unfortunately, this substance was found to cross react with pigment epithelial cells and its development has not been pursued.…”

Section: Discussionmentioning

confidence: 99%

Prevention of lens capsule opacification with ARC neodymium:YAG laser photolysis after phacoemulsification

Wehner¹,

Waring²,

Mamalis³

et al. 2010

Journal of Cataract and Refractive Surgery

View full text Add to dashboard Cite

We describe a technique that uses a neodymium:YAG (Nd:YAG) laser photolysis system to prevent lens capsule opacification. The photolysis instrument consists of a 1064 nm Nd:YAG laser transmitted along a fiber-optic cable into a handpiece containing an angulated titanium plate that the laser beam strikes, creating plasma and a shockwave that exits the handpiece through an aperture. Under direct visualization, the shockwave is aimed at the inner surface of the anterior capsule, where it removes LECs and proteoglycan attachment molecules; the shockwave probably extends to the capsule fornix, destroying germinal epithelial cells. We report preliminary results in 12 eyes followed for approximately 2.5 years in which the treated nasal anterior capsule remained clear or with only slight opacity and the untreated temporal capsule developed moderate to severe opacification.

show abstract

“…In both circumstances, the concentration of drug declined rapidly. 10,[13][14][15] Therefore, to achieve a therapeutic effect, high concentrations were often required, with the attendant risk for ocular toxicity. 3,[16][17][18] Tranilast, N-(3,4-dimethoxycinnamoyl)-anthranilic acid, is an antiallergy drug introduced to treat and prevent bronchial asthma and allergic rhinitis.…”

Section: J Cataract Refract Surg 2007; 33:2122-2128 Q 2007 Ascrs and mentioning

confidence: 99%

Safety and efficacy of intracapsular tranilast microspheres in experimental posterior capsule opacification

Wang¹,

Zhang²,

Jackson³

et al. 2007

Journal of Cataract and Refractive Surgery

View full text Add to dashboard Cite

show abstract

Inhibition of posterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results

Cited by 49 publications

References 4 publications

Ribosome-inactivating proteins: progress and problems

Ribosome-inactivating proteins: progress and problems

Prevention of lens capsule opacification with ARC neodymium:YAG laser photolysis after phacoemulsification

Safety and efficacy of intracapsular tranilast microspheres in experimental posterior capsule opacification

Contact Info

Product

Resources

About